Given Imaging to Host Fourth Quarter and Full Year 2010 Financial Results Conference Calls
January 24 2011 - 7:00AM
Marketwired
Given Imaging (NASDAQ: GIVN), today announced that the company will
host conference calls on Wednesday, February 16, 2011 to discuss
fourth quarter and full-year 2010 financial results. The company
plans to release results following the close of U.S. financial
markets on Tuesday, February 15, 2011.
The company will host a conference call in English at 9:00am ET
on Wednesday, February 16, 2011. To participate in this
teleconference, please dial 888-631-3389 fifteen minutes before the
conference is scheduled to begin. Callers outside of the U.S.
should dial 913-312-1520. The call will also be webcast live at
www.givenimaging.com. A replay of the call will be available for
two weeks on the company's website, or until March 2, 2011 by
dialing 888-203-1112. Callers outside of the U.S. should dial
719-457-0820. The replay participant code is 5242909.
A separate conference call in Hebrew will take place on February
16, 2011 at 2:00pm Israel time, 7:00 am ET. To access this call,
please dial +972 3 918 0609 ten minutes before the conference is
scheduled to begin. A replay of the call will be available from
February 16 until February 18 by dialing +972 3 925 5901.
About Given Imaging Ltd. Since 2001, Given
Imaging has advanced gastrointestinal visualization by developing
state-of-the art, patient-friendly tools based on its PillCam®
Platform. PillCam® capsule endoscopy uses wireless technology and
advanced software to provide physicians with clear images of the
small intestine via PillCam® SB and the esophagus through PillCam®
ESO. The PillCam® COLON, which is an investigational device in the
U.S., is designed to visualize the colon. The PillCam® capsules are
miniature video cameras that patients ingest. Given Imaging's other
capsule products include Agile™ patency capsule, to verify
intestinal patency, and Bravo®, the only wireless, catheter-free,
48-hour pH test commercially available for pH testing to assess
gastroesophageal reflux disease (GERD). In April, 2010, Given
Imaging acquired Sierra Scientific Instruments, the leading
provider of specialty GI diagnostic solutions and pioneer of
high-resolution manometry for assessing gastrointestinal motility.
Sierra Scientific is now a wholly-owned subsidiary of Given
Imaging. Given Imaging's headquarters, manufacturing and R&D
facilities are located in Yoqneam, Israel, with operating
subsidiaries in the United States, Germany, France, Japan,
Australia, and Hong Kong. For more information, please visit
www.givenimaging.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, projections about our business and
our future revenues, expenses and profitability. Forward-looking
statements may be, but are not necessarily, identified by the use
of forward-looking terminology such as "may," "anticipates,"
"estimates," "expects," "intends," "plans," "believes," and words
and terms of similar substance. Forward-looking statements involve
known and unknown risks, uncertainties and other factors which may
cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any
future events, results, performance, circumstances or achievements
expressed or implied by such forward-looking statements. Factors
that could cause actual events, results, performance, circumstances
or achievements to differ from such forward-looking statements
include, but are not limited to, the following: (1) our ability to
develop and bring to market new products, (2) our ability to
successfully complete any necessary or required clinical studies
with our products, (3) our ability to receive regulatory clearance
or approval to market our products or changes in regulatory
environment, (4) our success in implementing our sales, marketing
and manufacturing plans, (5) the level of adoption of our products
by medical practitioners, (6) the emergence of other products that
may make our products obsolete, (7) lack of an appropriate bowel
preparation materials to be used with our PillCam COLON capsule,
(8) protection and validity of patents and other intellectual
property rights, (9) the impact of currency exchange rates, (10)
the effect of competition by other companies, (11) the outcome of
significant litigation, (12) our ability to obtain reimbursement
for our product from government and commercial payors, (13)
quarterly variations in operating results, (14) the possibility of
armed conflict or civil or military unrest in Israel, (15) the
impact of global economic conditions, (16) our ability to
successfully integrate acquired businesses, (17) changes and
reforms in applicable healthcare laws and regulations, and (18)
other risks and factors disclosed in our filings with the U.S.
Securities and Exchange Commission, including, but not limited to,
risks and factors identified under such headings as "Risk Factors,"
"Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the
Company's Annual Report on Form 20-F for the year ended December
31, 2009. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except for the Company's ongoing obligations to
disclose material information under the applicable securities laws,
it undertakes no obligation to release publicly any revisions to
any forward-looking statements, to report events or to report the
occurrence of unanticipated events.
For further information contact: Fern Lazar/David Carey
Lazar Partners Ltd. 212 867 1768 Email Contact Email Contact
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Oct 2023 to Oct 2024